Kim Y T, Park J-Y, Jeon Y K, Park S J, Song J Y, Kang C H, Sung S W, Kim J H
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Dis Esophagus. 2009;22(2):143-50. doi: 10.1111/j.1442-2050.2008.00862.x. Epub 2008 Oct 1.
There has been no clear evidence demonstrating whether DNA hypermethylation can affect the prognosis of esophageal cancer. We collected tissue from 50 cases of squamous cell carcinoma of the esophagus and tested them for DNA hypermethylation using methylation-specific polymerase chain reaction. CpG island hypermethylations were observed in 10% for p16, 34% for RARbetaP2, 46% for adenomatosis polyposis coli (APC), 14% for RASSF1A, 84% for FHIT, and 8% for hMLH1. APC promoter hypermethylation was frequently found in patients without lymph node metastasis compared with those with lymph node metastasis (62.5% : 30.8%, P = 0.025). The number of metastatic lymph nodes were lower in patients with APC promoter hypermethylation (0.87 +/- 0.30 : 3.07 +/- 0.72, P = 0.008). Excluding operative mortalities and incomplete resections, 42 patients were analyzed for long-term outcome. During the mean follow-up period of 35 months, 17 developed recurrence and 14 died of cancer. Ten patients died of other causes. In univariable analysis, unmethylation of APC (P = 0.0015) and FHIT (P = 0.0044), as well as presence of lymph node metastasis (P = 0.0038), were risk factors for recurrence. In multivariable analysis, lymph nodes metastasis (P = 0.050) and unmethylation of APC promoter (P = 0.023) remained as significant risk factors. In conclusion, promoter hypermethylation of the APC gene is related to a lower number of metastatic lymph nodes and to superior prognosis in terms of recurrence, which suggests it might be involved in the process of lymph node metastasis in esophageal cancer.
尚无明确证据表明DNA高甲基化是否会影响食管癌的预后。我们收集了50例食管鳞状细胞癌组织,并使用甲基化特异性聚合酶链反应检测其DNA高甲基化情况。观察到p16的CpG岛高甲基化率为10%,RARbetaP2为34%,腺瘤性息肉病 coli(APC)为46%,RASSF1A为14%,FHIT为84%,hMLH1为8%。与有淋巴结转移的患者相比,无淋巴结转移的患者中APC启动子高甲基化更为常见(62.5% : 30.8%,P = 0.025)。APC启动子高甲基化的患者转移淋巴结数量较少(0.87 +/- 0.30 : 3.07 +/- 0.72,P = 0.008)。排除手术死亡率和不完全切除病例后,对42例患者进行了长期预后分析。在平均35个月的随访期内,17例出现复发,14例死于癌症。10例死于其他原因。单因素分析中,APC(P = 0.0015)和FHIT(P = 0.0044)的未甲基化以及淋巴结转移的存在(P = 0.0038)是复发的危险因素。多因素分析中,淋巴结转移(P = 0.050)和APC启动子的未甲基化(P = 0.023)仍然是显著的危险因素。总之,APC基因启动子高甲基化与转移淋巴结数量较少以及复发方面的较好预后相关,这表明它可能参与了食管癌的淋巴结转移过程。